Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
The telehealth platform posted a quarterly loss of $92.1 million, driven by higher expenses, including those tied to operations, technology and general and administrative functions.
Investing.com -- Hims & Hers missed first-quarter earnings estimates, posting a loss as weakness in its American operations offset gains overseas.
Shares of Hims & Hers Health sank late Monday after the company underperformed first-quarter earnings and revenue expectations, surprising Wall Street with a quarterly loss. The telehealth provider, which made a name for itself in the business of weight-loss drugs, posted a first-quarter loss of 40 cents a share, compared with profit of 20 cents a share a year ago. Wall Street was looking for a profit of 3 cents a share.
Telehealth company Hims & Hers Health (NYSE:HIMS) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 3.8% year on year to $608.1 million. On the other hand, next quarter’s outlook exceeded expectations with revenue guided to $690 million at the midpoint, or 6% above analysts’ estimates. Its GAAP loss of $0.40 per share was significantly below analysts’ consensus estimates.
HIMS broadens its digital health platform with Labs, menopause and testosterone care, global acquisitions and a Novo Nordisk GLP-1 tie-up.
The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.
The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.
The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.
The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.
The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.
The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.
The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations.
This week is peppered with potential market-moving events. Headlining are Tuesday’s inflation report, which will offer the latest glimpse of how the Iran war is affecting consumer prices, and President Trump’s long-awaited—and delayed—visit to China, with the war and tariffs likely to be central topics.
Why Hims & Hers Health is on investors’ radar Hims & Hers Health (HIMS) has drawn fresh attention after a recent move in its share price, with the stock closing at $25.65 and showing mixed returns over the past year. Investors are weighing that price against the company’s reported US$2.35b in revenue and US$128.37m in net income, along with multi year total returns that differ sharply from the past year’s performance. See our latest analysis for Hims & Hers Health. The recent pullback, with a...
Hims & Hers Health (NYSE:HIMS) has launched Labs AI, an AI care agent that provides users with personalized, clinically vetted interpretations of their lab results. The company is also expanding into FDA-approved GLP-1 weight loss medications through partnerships with major pharmaceutical companies, including Novo Nordisk and Eli Lilly. These moves come as NYSE:HIMS trades at $25.65, with the stock up 31.5% over the past 30 days but down 23.2% year to date and 50.1% over the past year. The...
Quarterly filings reveal markedly different revenue trajectories and margin profiles for these two healthcare platforms. What do their latest numbers indicate?
HIMS first-quarter 2026 results are likely to benefit from Labs and branded weight loss medications even as higher costs and GLP-1 scrutiny linger.
Senseonics (SENS) delivered earnings and revenue surprises of -9.23% and +16.81%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Standard BioTools (LAB) delivered earnings and revenue surprises of 0.00% and +13.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Wondering whether Hims & Hers Health at US$26.33 still offers value, or if the best entry points are already behind you? This article focuses squarely on what the current price may imply. The stock has been volatile, with a 7 day return of a 5.7% decline, a 30 day return of 37.6%, a year to date return of a 21.2% decline, and a 1 year return of a 46.8% decline, set against a 3 year return that is very large and a 5 year return of 166.0%. Recent coverage has highlighted how Hims & Hers Health...
Hims & Hers Health, Inc. (HIMS) closed at $26.37 in the latest trading session, marking a -3.79% move from the prior day.
HIMS broadens its DTC platform with GLP-1 access, a new Benefits hub and global expansion to broaden convenient, personalized care.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is HIMS a good stock to buy? We came across a bullish thesis on Hims & Hers Health, Inc. on Investment Ideas by Antonio’s Substack by Antonio Linares. In this article, we will summarize the bulls’ thesis on HIMS. Hims & Hers Health, Inc.’s share was trading at $29.76 as of April 21st. HIMS’s trailing and forward […]
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.
Investing.com -- Abortion access in the United States was dealt a legal blow on Friday after a Federal Appeals Court issued a temporary stay halting the distribution of Mifepristone by mail.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
